

1           **Assessing the impact of a national clinical guideline for the**  
2           **management of chronic pain on opioid prescribing rates: A**  
3           **controlled interrupted time series analysis**

4       Harry L. Hébert<sup>1\*</sup>, Daniel R. Morales<sup>1</sup>, Nicola Torrance<sup>2</sup>, Blair H. Smith<sup>1,3</sup>, Lesley A. Colvin<sup>1,3</sup>

5       1. Division of Population Health and Genomics, School of Medicine, Ninewells  
6       Hospital and Medical School, University of Dundee, Dundee, UK.

7       2. School of Nursing, Midwifery & Paramedic Practice, Robert Gordon University,  
8       Aberdeen, UK.

9       3. Joint senior authors

10

11       **Short title:** Impact of a clinical guideline on national opioid prescribing

12

13       **\*Corresponding author:** Harry L. Hébert, Ph.D.

14       Chronic Pain Research Group

15       Division of Population Health and Genomics

16       Mackenzie Building

17       Ninewells Hospital and Medical School

18       Kirsty Semple Way

19       Dundee

20       DD2 4BF

21

22       **Tel:** +44 (0)1382 383191

23       **Email:** [h.hebert@dundee.ac.uk](mailto:h.hebert@dundee.ac.uk)

24

25       **Keywords:** Opioids, prescribing rates, interrupted time series analysis, clinical  
26       guideline, chronic pain

## 1 **Abstract**

2 **Background:** Opioids can be effective analgesics, but long-term use may be  
3 associated with harms. In 2013, the first national, comprehensive, evidence-based  
4 pain management guideline was published, from the Scottish Intercollegiate Guideline  
5 Network (SIGN 136: Management of Chronic Pain) with key recommendations on  
6 analgesic prescribing. This study aimed to examine the potential impact on national  
7 opioid prescribing rates in Scotland.

8 **Methods:** Trends in national and regional community opioid prescribing data for  
9 Scotland were analysed from quarter one (Q1) 2005 to Q2 2020. Interrupted time  
10 series regression examined the association of SIGN 136 publication with prescribing  
11 rates for opioid-containing drugs. Gabapentinoid prescribing was used as an outcome  
12 control.

13 **Results:** After a positive prescribing trend pre-publication, the timing of SIGN 136  
14 publication was associated with a negative change in trend of opioid prescribing rates  
15 (-2.82 items per 1,000 population per quarter [PTPPQ];  $P < 0.01$ ). By Q2 2020, the  
16 relative reduction in opioid prescribing rate was -20.67% (95% CI: -23.67, -17.77). This  
17 persisted after controlling for gabapentinoid prescribing and was mainly driven by  
18 reduction in weak opioids, whereas strong opioid prescribing rates continued to rise.  
19 Gabapentinoid prescribing showed a significant rise in level (8.00 items per 1,000  
20 population;  $P = 0.01$ ) and trend (0.27 items PTPPQ;  $P = 0.01$ ) following SIGN 136  
21 publication.

22 **Conclusions:** Publication of SIGN 136 was associated with a reduction in opioid  
23 prescribing rates. This suggests that changes in clinical policy through evidence-based  
24 national clinical guidelines may affect community opioid prescribing, though this may  
25 be partially replaced by gabapentinoids, and other factors may also contribute.

## 1 **Introduction**

2 Chronic pain is a common and complex problem, with a debilitating impact on quality  
3 of life<sup>1</sup>. Whilst there is often no cure, opioids have been commonly used to treat  
4 patients with the disorder<sup>2</sup>. There is good evidence for their efficacy in acute and  
5 cancer-related pain, but very limited high-quality evidence for effectiveness in long-  
6 term management of chronic non-malignant pain<sup>3</sup>. Inadequate pain relief with opioids  
7 can lead to dose escalation and tolerance, with risks of major adverse events such as  
8 dependence, addiction, overdose and death<sup>4</sup>.

9 Opioid use has been increasing steadily worldwide, with the World Drug Report –  
10 2021 estimating that nearly 62 million people (aged 15-64) used opioids globally in  
11 2019<sup>5</sup>. In particular, the increase in prescribing of opioids in the USA from the late  
12 1990s to the early 2010s has been well documented<sup>6</sup>. Possible explanations for this  
13 increase include an ageing population at greater risk of developing chronic pain  
14 conditions, the publication of clinical guidelines recommending opioids for chronic non-  
15 cancer pain, despite insufficient good quality evidence, (non-evidence-based) changes  
16 in recommendations on use from professional bodies, and effective marketing from  
17 pharmaceutical companies<sup>7</sup>. This increase in opioid use has given rise to the “opioid  
18 epidemic” in the USA and there are concerns a similar situation could be happening in  
19 the UK, including Scotland<sup>8,9</sup>.

20 In December 2013, the Scottish Intercollegiate Guideline Network (SIGN), in  
21 consultation with the National Chronic Pain Steering Group of the Scottish  
22 Government and key stakeholders, published the first comprehensive evidence-based  
23 guideline for the assessment and management of chronic, non-malignant pain in  
24 adults (SIGN 136)<sup>10</sup>. SIGN 136 identified a research gap around understanding rates  
25 and effects of opioid prescribing in Scotland<sup>11</sup>. A resulting investigation of Scottish  
26 data revealed that prescribing rates of strong opioids doubled in the 10-year period  
27 leading up to publication of SIGN 136 (2003-2012)<sup>12</sup>. One aspiration of SIGN 136 was  
28 to influence safe and appropriate use of opioids in chronic pain, reducing unnecessary  
29 and potentially harmful prescribing. Whilst it is recognised that clinical practice  
30 guidelines have the potential to increase the quality of care, systematic analysis of  
31 their impact is not common<sup>13</sup>.

32 Gabapentinoids (mainly gabapentin and pregabalin) are licensed for the treatment of  
33 peripheral and central neuropathic pain, with strong evidence for their effectiveness<sup>14</sup>  
34 <sup>15</sup>. In contrast to opioids, SIGN 136 key recommendations did not caution about risks

1 of harm related to gabapentinoid misuse, as, at the time of publication, there was little  
2 evidence of this.

3 Opioid prescribing rates have now become one of National Health Service (NHS)  
4 Scotland's key National Therapeutic indicators, a set of prescribing indicators in  
5 specific therapeutic areas that can be used to compare prescribing behaviours against  
6 established guidelines<sup>16</sup>. These indicators clearly show that opioid prescribing rates  
7 are beginning to fall across Scotland. However, to the best of our knowledge, the  
8 potential impact of SIGN 136 on opioid prescribing rates has not been investigated.  
9 Therefore, this study aimed to analyse opioid prescribing rates in Scotland before and  
10 after SIGN 136 publication and to compare these to gabapentinoids.

## 1 **Methods**

2 We followed the Framework for Enhanced Reporting of Interrupted Time Series  
3 Studies (FERITS) statement<sup>17</sup>, an adaptation of the Transparent Reporting of  
4 Evaluations with Nonrandomised Designs (TREND) statement<sup>18</sup>, for the reporting of  
5 this study (Supplementary Table S1).

6

## 7 **Study Design**

8 This study was an interrupted time series analysis of national level prescribing data on  
9 opioid analgesics prescribed in primary care and dispensed in by community  
10 pharmacies, to test the hypothesis that SIGN 136 is associated with a significant  
11 change in opioid prescribing trend. Gabapentinoid prescribing data were also obtained  
12 and used to control for potential confounding from other interventions. The study  
13 period was from January 2005 to June 2020 and incorporated the SIGN 136  
14 publication date (December 2013).

15

## 16 **Data Source**

17 Data on all opioids and gabapentinoids, prescribed through primary care (in the  
18 community) by general practitioners (GPs) and non-medical prescribers and  
19 dispensed by community pharmacists in Scotland, were obtained from Public Health  
20 Scotland (PHS). This was based on aggregated and publicly available data<sup>19</sup>. PHS  
21 (<https://www.publichealthscotland.scot/>) is part of NHS Scotland and holds individual-  
22 level prescribing data through the Prescribing Information System (PIS), which is a  
23 national data system, set up in 2009, that captures all NHS prescriptions dispensed  
24 and reimbursed in the community ([https://www.ndc.scot.nhs.uk/National-  
25 Datasets/data.asp?SubID=9](https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=9)). In the UK, healthcare policy is devolved to the individual  
26 nations and, in Scotland, community prescriptions are free at the point of delivery.  
27 Pharmacists are reimbursed for the prescriptions they dispense. The PIS covers the  
28 population of Scotland (approximately 5.3 million), with GPs accounting for  
29 approximately 95% of community prescribing, and a capture rate of 98.7% from  
30 prescription forms<sup>20</sup>. Also included in the data request were annual mid-year  
31 population estimates for Scotland as of 30<sup>th</sup> June each year.

32 Formal ethical approval was not required as the study used publicly available data  
33 which contained no patient or prescriber identifiable information.

## 1 **Publication of SIGN 136**

2 The Scottish Intercollegiate Guideline Network (SIGN) was established in 1993 by the  
3 Scottish Medical Royal Colleges and is now part of Healthcare Improvement Scotland,  
4 part of NHS Scotland. It produces evidence-based clinical practice guidelines for use  
5 across NHS Scotland, with accredited methodology<sup>21</sup>, and is a member organisation  
6 of the Guidelines International Network (<https://g-i-n.net/>). SIGN 136 was published in  
7 December 2013 and, after a systematic review of the evidence, included key  
8 recommendations and best practice statements on safe and effective opioid  
9 prescribing (Supplementary Box S1). The Scottish Government requires Health  
10 Boards to identify areas of concern where they are not meeting SIGN's Key  
11 recommendations, so they become important benchmark standards for care. The  
12 Scottish Government also provides regular feedback of opioid prescribing data to  
13 individual GP Practices as National Therapeutic Indicators, to ensure implementation  
14 of SIGN 136. Therefore, it has formed the basis of pain service provision and  
15 improvement in Scotland since its publication. The guideline is aimed at all healthcare  
16 professionals involved in the assessment and management of adult patients with  
17 chronic non-malignant pain in non-specialist settings. At the time of publication, hard  
18 copies were disseminated to all primary care practices across Scotland and the  
19 guideline is available for download from SIGN's website  
20 (<https://www.sign.ac.uk/assets/sign136.pdf>). A patient version was also available<sup>22</sup>.  
21 The opioids section of this guideline (section 5.3 "Opioids") was subsequently updated  
22 in August 2019<sup>23</sup>. However, for this study we only considered the original 2013  
23 publication as the "intervention".

24 To control for any potential unforeseen confounders acting in Scotland, such as  
25 changes in prevalence of chronic pain or changes in policy involving the use of  
26 pharmacological interventions for chronic pain in general, we decided to use  
27 gabapentinoid prescribing as a comparison. SIGN 136 included guidance for  
28 gabapentinoids (gabapentin and pregabalin), though in contrast to opioids there were  
29 no specific recommendations warning of the potential for abuse, addiction or other  
30 side effects (Supplementary Box S2). Therefore, it was hypothesised that  
31 gabapentinoid prescribing rates would not have reduced as a result of SIGN 136  
32 publication.

33

34

## 1 **Outcome**

2 The primary outcome was the number of opioid prescription items dispensed per  
3 1,000 population per quarter (PTPPQ). A prescription may contain multiple  
4 pharmaceutical products. If a prescription form includes three medicines, it is counted  
5 as three prescription items. The control outcome was the number of gabapentinoid  
6 (gabapentin and pregabalin) items dispensed PTPPQ. Quarters were defined as  
7 January to March (Q1), April to June (Q2), July to September (Q3) and October to  
8 December (Q4), inclusive. A list of all relevant opioid-containing drugs included in the  
9 study is given in Supplementary Table S2. These include single and compound  
10 analgesics found in chapter 4.7.2 (“Opioid analgesics”) of the British National  
11 Formulary (BNF)<sup>24</sup> as well as additional combination products of opioids (e.g. co-  
12 codamol) found elsewhere. Gabapentin and pregabalin are detailed in chapter 4.8.1  
13 (“Control of epilepsy”) of the BNF. The dataset includes all items prescribed through  
14 the NHS in primary care in Scotland (which provides the first point of contact for  
15 patients in the healthcare system, usually through GP practices), dispensed in the  
16 community in the UK and submitted for reimbursement. Data on items prescribed but  
17 not subsequently submitted for dispensing by the patient (estimated to be ~6%)<sup>20</sup> or  
18 dispensed but not submitted for reimbursement by the pharmacy are not currently held  
19 by PHS. The small number of private prescriptions, hospital and direct supply of  
20 medicines to patients (e.g. prescriptions supplied through specialist clinics) were not  
21 included.

22

## 23 **Statistical Analysis**

24 Linear regression was used to analyse the impact of SIGN 136 on opioid and  
25 gabapentinoid prescribing trends nationally. The model for the analysis is provided in  
26 Box 1. As part of this process, plots of each time series were studied to check that the  
27 assumption of linearity was appropriate in each analysis.

28 The analysis of opioid prescribing trends was stratified according to opioid strength  
29 (weak or strong), and recipients’ age (0-29, 30-49, 50-69 and 70+ years) and gender.  
30 The stratification of drugs by strength was based on their status in SIGN 136 with  
31 codeine, dihydrocodeine, meptazinol and tramadol considered weak opioids and  
32 buprenorphine, diamorphine, dipipanone, fentanyl, hydromorphone, methadone,  
33 morphine, oxycodone, papaveretum, pentazocine, pethidine and tapentadol  
34 considered strong opioids. Compound drugs were classified according to the parent

1 opioid (Supplementary Table S2). Level and slope change models were used to test  
2 the hypothesised immediate and longer-term impact on prescribing behaviour that the  
3 publication of SIGN 136 would have had.

4 A controlled interrupted time series approach was used to compare opioid prescribing  
5 trends to gabapentinoid prescribing trends; weak opioid vs strong opioid prescribing;  
6 and prescribing between men and women.

7 All analyses used data from Q1 2005 to Q2 2020 inclusive, apart from the analyses  
8 involving age and gender, where data were only available between Q1 2010 and Q2  
9 2020. The publication of SIGN 136 (i.e. the “intervention”) was defined as Q4, 2013,  
10 providing 36 data points before the publication (16 data points for the age and gender  
11 analyses) and 26 data points after the publication.

12 The effect of the publication was presented as the relative percentage change in  
13 prescribing rate at Q2 2020 compared to the predicted value at the same time point  
14 had pre-publication trends continued (the counterfactual, calculated from the model  
15 coefficient estimates). The 95% confidence intervals (CI) were calculated using model  
16 bootstrapping approaches<sup>25</sup>. All models were checked for autocorrelation using the  
17 Durbin-Watson statistic. A range of 1.50-2.50 was used to indicate an acceptable level  
18 of autocorrelation. Models outside this range were corrected using Newey-West  
19 standard errors.

20 All analyses were carried out using the statistical software R (version 4.0.3)<sup>26</sup>.



## 1 **Results**

### 2 **Summary Statistics**

3 The mid-year population estimates from 2005 to 2020 for the whole of Scotland are  
4 given in Supplementary Table S3. The estimated population size of Scotland was  
5 5,110,200 in 2005 and 5,466,000 in 2020. A breakdown of the mid-year population  
6 estimates by age and gender is given in Supplementary Table S4 from 2010-2020.

7 Between Q1 2005 and Q2 2020, a total of 91,210,542 prescription items of the  
8 specified opioid or opioid-containing combination drugs included in this study were  
9 dispensed across Scotland. At the same time, a total of 12,036,499 prescriptions items  
10 of gabapentinoids were dispensed across Scotland. The total number of items of each  
11 drug prescribed is given in Supplementary Table S2.

12

### 13 **Overall Analysis**

14 Across the whole of Scotland, the number of opioid prescription items rose from  
15 1,040,276 in Q1 2005 to 1,608,984 in Q4 2013, an increase of 54.7%. Since the  
16 publication of SIGN 136 (Q4 2013), the number of opioid prescriptions has gradually  
17 fallen to 1,499,400 items in Q2 2020, a decrease of 6.8% (Figure 1).

18 There was a significant positive trend in opioid prescribing rates pre-publication (2.19  
19 items PTPPQ;  $P < 0.01$ ), followed by no significant level change, and a significant  
20 change in trend following the publication (-2.82 items PTPPQ;  $P < 0.01$ ). Opioid  
21 prescribing rates began to fall post-publication at -0.64 items PTPPQ and at the end of  
22 the study period the relative change was estimated to be -20.67% (95% CI: -23.67, -  
23 17.77) compared to the counterfactual (Table 1).

24 In comparison, there was a significant positive trend in gabapentinoid prescribing pre-  
25 publication (0.88 items PTPPQ;  $P < 0.01$ ), followed by a significant increase in level  
26 (8.00 items per 1,000 population [PTP];  $P < 0.01$ ), and a significant positive change in  
27 trend post-publication (0.27 items PTPPQ;  $P = 0.01$ ). The interrupted time series  
28 analysis and prescribing rates for gabapentinoids are presented in Table 1 and Figure  
29 1.

30 When opioid prescribing was adjusted for gabapentinoid prescribing (Table 2), the  
31 significant change in trend post-publication was maintained (-3.09 items PTPPQ;  
32  $P < 0.01$ ). There was also a significant negative difference in level change compared to

1 gabapentinoids (-9.09 items PTP; P=0.02). The adjusted publication effect on opioid  
2 prescribing rate at the end of the study period was calculated to be -24.85% (95% CI: -  
3 28.25, -21.61).

4

## 5 **Stratified Analysis**

6 When stratifying opioid prescribing by strength (Figure 2), both weak (-2.27 items  
7 PTPPQ; P<0.01) and strong opioids (-0.55 items PTPPQ; P<0.01) showed significant  
8 negative changes in trend post-publication, but non-significant changes in level (Table  
9 3). However, there was a significantly greater negative change in trend for weak  
10 opioids than for strong opioids in the adjusted analysis (-1.72 items PTPPQ; P<0.01;  
11 Supplementary Table S5). Post-publication, weak opioid prescribing rates began to fall  
12 at -0.91 items PTPPQ, whereas strong opioids rates continued to rise at 0.27 items  
13 PTPPQ. The relative change was estimated to be -21.68% (95% CI: -24.75, -18.57)  
14 for weak opioids and -17.49% (95% CI: -20.15, -14.87) for strong opioids.

15 In the gender analysis for opioids, both women (-3.26 items PTPPQ; P<0.01) and men  
16 (-2.52 items PTPPQ; P<0.01) showed significant negative changes in trend post-  
17 publication, but non-significant changes in level (Supplementary Figure S1). Opioid  
18 prescribing rates began to fall post-publication for both women (-0.54 items PTPPQ)  
19 and men (-0.44 items PTPPQ; Supplementary Table S6). There were no significant  
20 differences between the genders in the adjusted analysis, in terms of the post-  
21 publication effects (Supplementary Table S7) and the relative change was estimated  
22 to be -19.11% (95% CI: -23.61, -13.13) for women and -21.54% (95% CI: -25.88, -  
23 15.64) for men.

24 Finally, in the age analysis (Supplementary Figure S2) all groups showed non-  
25 significant changes in level except the >70 years old group (13.61 items PTP; P=0.03)  
26 and all the groups showed significant negative changes in trend post-publication (0-29  
27 years: -0.74; 30-49 years: -5.47; 50-69 years: -3.21; >70 years: -3.46 items PTPPQ  
28 respectively). All the age groups showed significant negative post-publication trends  
29 (0-29 years: -0.41; 30-49 years: -1.15; >70 years: -0.27 items PTPPQ respectively),  
30 except the 50-69 year group. The relative changes were estimated to be -36.13 (95%  
31 CI: -44.43, -22.56) in 0-29 years, -31.64 (95% CI: -35.43, -26.81) in 30-49 years, -  
32 15.29 (95% CI: -21.33, -6.24) in 50-69 years and -12.04 (95% CI: -16.25, -6.33) in >70  
33 years (Supplementary Table S8).

## 1 **Discussion**

### 2 **Summary**

3 In this study, publication of a national clinical guideline on management of chronic pain  
4 (SIGN 136) in 2013 was associated with a significant negative change in trend in  
5 primary care opioid prescribing in Scotland that resulted in a relative reduction of 21%  
6 by Q2 2020. This finding persisted when controlling for gabapentinoids, which was not  
7 associated with any similar changes in prescribing trend. Stratified analyses by opioid  
8 strength, age category and gender showed that SIGN 136 was associated with a  
9 significant negative change in trend in all groups. Despite this, prescribing rates of  
10 strong opioids continued to rise post-publication, albeit at a slower rate than pre-  
11 publication. To the best of our knowledge this is the first study to analyse changes in  
12 opioid prescribing trends in Scottish primary care, and to examine the association of  
13 prescribing rates with a specific intervention intended to influence these.

14

### 15 **Interpretation**

16 Increasing opioid prescribing in the UK and elsewhere has been well documented<sup>27-30</sup>.  
17 This is also the case in Scotland where prescribing of opioids has increased both  
18 locally and nationally<sup>9 12</sup>. However, the time-period covered by the Scottish studies  
19 was prior to the publication of SIGN 136. Similar increases have been identified more  
20 recently across the UK<sup>31</sup>. This continuing increase in opioid prescribing rate across the  
21 UK beyond 2013 appears to be in contrast with the results from the current study.

22 However, we found that this decrease in prescribing numbers and most of the change  
23 in trend associated with SIGN 136 was being driven by weak opioids, with strong  
24 opioid prescribing rates continuing to increase. This increase in strong opioid  
25 prescribing rates appears to be in line with a previous study in Wales<sup>27</sup>. This may  
26 reflect a marked change in prescribing behaviour for weak opioids, whilst changes in  
27 prescribing behaviour for strong opioids has been slower. However, weak opioids  
28 continued to be much more frequently prescribed than strong opioids overall.

29 In addition to the opioid findings, there was also a significant increase in  
30 gabapentinoid prescribing trend. A possible reason for this could be an increase in the  
31 number of neuropathic pain cases being diagnosed and treated, particularly as  
32 gabapentinoids are recommended first or second line treatment for neuropathic pain in  
33 national and international guidelines<sup>32 33</sup>. However, this is unlikely to account for all of

1 the increase in gabapentinoid prescribing rates<sup>34</sup>. Another potential explanation is that  
2 the publication of SIGN 136 has led to a swap of prescription of opioids for  
3 gabapentinoids. Gabapentinoids are licensed for the treatment of neuropathic pain,  
4 yet there is increasing evidence that they are being prescribed off-label for other forms  
5 of pain<sup>35</sup>, despite limited evidence for their effectiveness for non-neuropathic pain<sup>36 37</sup>.  
6 However, gabapentinoids have themselves recently been associated with increased  
7 rates of adverse outcomes and the increase in their use is a cause for concern<sup>38 39</sup>.  
8 This increase has prompted the reclassification of gabapentin and pregabalin as Class  
9 C controlled drugs in the UK (placing greater legal restrictions on their supply) and the  
10 complete removal of pregabalin from the formulary for neuropathic pain in Northern  
11 Ireland<sup>40</sup>.

12

### 13 **Strengths and Weaknesses**

14 Due to the epidemiological design of the study, the impact of other guidelines, policies  
15 and related interventions within Scotland cannot be ruled out. In the UK these include  
16 the reclassification of tramadol in 2013<sup>41</sup>, chronic pain initiatives<sup>42</sup> and an online  
17 resource, "Opioids Aware", to support prescribing of opioids for chronic pain<sup>43</sup>.  
18 Furthermore, initiatives outside of the UK such as the Helping to End Addiction Over  
19 the Long-term (HEAL) initiative in the USA<sup>44</sup> may have further influenced more recent  
20 prescribing practices in Scotland. Media coverage of the opioid epidemic in the USA is  
21 also likely to have raised awareness amongst the general public and patients may  
22 have gained a greater understanding of the risks of opioid treatments and other  
23 options available.

24 In contrast to the findings in this study of decreasing opioid prescribing rates since  
25 December 2013, it is interesting to note a previous study in which regulatory warnings  
26 about the cardiovascular safety of diclofenac in Scotland appeared to increase the  
27 rate of switching to opioids around the same time as SIGN 136 publication<sup>45</sup>. As a  
28 result, it is possible that without this influence, the negative change in opioid  
29 prescribing trend associated with SIGN 136 may have been greater.

30 A revised version of SIGN 136 was also published in August 2019, providing more up  
31 to date evidence-based guidance on opioid prescribing<sup>23</sup>. Through both this and the  
32 original version, SIGN 136 has been influential in driving UK and Scottish Government  
33 policy on chronic pain management and has been incorporated into clinical practice

1 with the publication of the Scottish National Prescribing Strategy for Chronic Pain<sup>46</sup>,  
2 the Royal College of Anaesthetists Quality Improvement Compendium<sup>47</sup> and the  
3 Medicines and Healthcare products Regulatory Agency guidance on the safe use of  
4 opioids<sup>48</sup>. The potential impact of the update has not yet been assessed and should  
5 be the focus of future studies. So too should the potential impact of the COVID-19  
6 pandemic, which has had a major impact on emergency and specialist care services  
7 with concern around a potential increase in opioid prescribing rates as patients turn to  
8 primary care<sup>49</sup>.

9 Regardless of the potential cause, the reduction in opioid prescribing trend described  
10 in this study demonstrates the important role that evidence-based clinical guidelines  
11 potentially play in prescribing behaviours. Previous studies have indicated that GPs'  
12 beliefs about whether or not opioids are appropriate for chronic non-cancer pain are a  
13 driver in whether to prescribe them, and a lack of a consistent approach and effective  
14 alternatives are barriers to deprescribing opioids, despite clear concerns about  
15 potential harms such as addiction, dependence and misuse<sup>50-52</sup>. This supports the  
16 need for dedicated guidelines, based on strong evidence.

17 This study also highlights interrupted time series analysis as a potential tool for  
18 assessing the impact of clinical guidelines. A previous study that used a similar  
19 approach found that the reclassification of tramadol as a Schedule 3 controlled  
20 substance in June 2014 was significantly associated with a reduction in tramadol  
21 utilisation in England and Wales<sup>41</sup>.

22 Despite focussing on prescribing rates in relation to SIGN 136, we were unable to  
23 assess other opioid-related outcomes, such as abuse, misuse and overdose. Since a  
24 key aim of SIGN 136 is to improve patient quality of life, it would be interesting to see if  
25 incidence rates for these outcomes have fallen in line with opioid prescribing since  
26 publication of SIGN 136, as would be expected given their close association<sup>53</sup>. Recent  
27 data from Scotland show opioid-related deaths rates are continuing to rise, though this  
28 could be due to illicit use as well as iatrogenic use<sup>54</sup>.

29

## 30 **Conclusion**

31 In conclusion, opioid prescribing rates have been falling in Scotland since 2013. Whilst  
32 this effect cannot be definitively linked to the publication of SIGN 136, it at least  
33 suggests that changes in Scottish clinical and government policy relating to chronic

1 pain management, most of which have been inspired by its publication, are having a  
2 positive effect on opioid prescribing practices in primary care. This highlights the  
3 importance of providing continued robust clinical advice, based on up-to-date  
4 evidence, for safe and effective treatment for chronic pain.

5

## 6 **Details of Author Contributions**

7 Study conception and design: B.H.S. and L.A.C.

8 Data acquisition: H.L.H.

9 Data analysis and interpretation: all authors

10 Drafting the article and revising for important intellectual content: all authors

11 Final approval of the published version: all authors.

12

## 13 **Acknowledgements**

14 We acknowledge the help and support of Public Health Scotland and the Health  
15 Informatics Centre, University of Dundee for managing and supplying the anonymised  
16 data.

17

## 18 **Conflict of Interest**

19 L.A.C. chaired the Guideline Development Group for the Scottish Intercollegiate  
20 Guideline Network publication, "Management of Chronic Pain" to which this paper  
21 refers, proposed an update due to changing evidence, and contributed to the update  
22 of the opioids section. She has been Vice Chair of SIGN since October 2020 and was  
23 a member of the Scottish Government group that developed the National Prescribing  
24 Strategy for Chronic Pain.

25 B.H.S. was a member of the Guideline Development Group for the Scottish  
26 Intercollegiate Guideline Network publication, "Management of Chronic Pain" to which  
27 this paper refers and contributed to the update of the opioids section. He was the  
28 Scottish Government's National Lead Clinician for Chronic Pain (2014 to 2021) and  
29 was a member of the Scottish Government group that developed the National  
30 Prescribing Strategy for Chronic Pain.

31 D.R.M. is supported by a Wellcome Trust Clinical Research Development Fellowship  
32 (Grant 214588/Z/18/Z) and reports grants from the Chief Scientist Office (CSO),

1 Health Data Research UK (HDR-UK) and the National Institute of Health Research  
2 (NIHR), outside of the submitted work.

3 H.L.H., and N.T. declare that they have no conflicts of interest.

4

5 **Funding**

6 No external financial support was received for this study.

## References

1. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1789–858
2. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. *JAMA* 2016; **315**: 1624–45
3. Krebs EE, Gravelly A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. *JAMA* 2018; **319**: 872–82
4. Higgins C, Smith BH, Matthews K. Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. *Br J Anaesth* 2018; **120**: 1335–44
5. United Nations Office on Drugs and Crime. World Drug Report 2021. New York; 2021. Available from: <https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html>
6. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. *MMWR Morb Mortal Wkly Rep* 2011; **60**: 1487–92
7. Smith BH, Fletcher EH, Colvin LA. Opioid prescribing is rising in many countries. *BMJ* 2019; **367**: l5823
8. Kimber J, Hickman M, Strang J, Thomas K, Hutchinson S. Rising opioid-related deaths in England and Scotland must be recognised as a public health crisis. *Lancet Psychiatry* 2019; **6**: 639–40
9. Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995-2010: Repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. *Eur J Pain* 2015; **19**: 59–66
10. Scottish Intercollegiate Guideline Network. SIGN 136: Management of chronic pain: A national clinical guideline. Edinburgh; 2013. Available from: <https://www.sign.ac.uk/assets/sign136.pdf>
11. Colvin LA, Stein A, Smith BH. Managing chronic pain: a clinical challenge: new SIGN guidelines provide a practical evidence-based approach and identify research gaps. *Br J Anaesth* 2014; **112**: 9–12
12. Torrance N, Mansoor R, Wang H, et al. Association of opioid prescribing practices with chronic pain and benzodiazepine co-prescription: a primary care data linkage study. *Br J Anaesth* 2018; **120**: 1345–55
13. Lugtenberg M, Burgers JS, Westert GP. Effects of evidence-based clinical practice guidelines on quality of care: a systematic review. *Qual Saf Health Care* 2009; **18**: 385–92
14. Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. *Cochrane Database Syst Rev* 2019; **1**: CD007076



15. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. *Cochrane Database Syst Rev* 2017; **6**: CD007938
16. Public Health Scotland. National therapeutic indicators data visualisation. 2021 [cited 2022 Jan 13]. Available from: <https://www.publichealthscotland.scot/publications/national-therapeutic-indicators-data-visualisation/national-therapeutic-indicators-data-visualisation-data-to-march-2021/dashboard-data-to-march-2021/>
17. The Equator Network. Reporting guidelines under development for observational studies. 2021 [cited 2021 Aug 19]. Available from: <https://www.equator-network.org/library/reporting-guidelines-under-development/reporting-guidelines-under-development-for-observational-studies/#92>
18. Des Jarlais DC, Lyles C, Crepaz N, The Trend Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. *Am J Public Health* 2004; **94**: 361–6
19. Public Health Scotland. Prescriptions in the Community. 2022 [cited 2022 Jan 18]. Available from: <https://www.opendata.nhs.scot/dataset/prescriptions-in-the-community>
20. Alvarez-Madrado S, McTaggart S, Nangle C, Nicholson E, Bennie M. Data Resource Profile: The Scottish National Prescribing Information System (PIS). *Int J Epidemiol* 2016; **45**: 714F-715F
21. Scottish Intercollegiate Guideline Network. SIGN 50: A guideline developer's handbook. Edinburgh; 2019. Available from: [https://www.sign.ac.uk/media/1050/sign50\\_2019.pdf](https://www.sign.ac.uk/media/1050/sign50_2019.pdf)
22. Scottish Intercollegiate Guidelines Network. Managing chronic pain. Edinburgh; 2019. Available from: [https://www.sign.ac.uk/media/1175/pat136\\_2019.pdf](https://www.sign.ac.uk/media/1175/pat136_2019.pdf)
23. Scottish Intercollegiate Guideline Network. SIGN 136: Management of chronic pain: A national clinical guideline [revised edition]. Edinburgh; 2019. Available from: [https://www.sign.ac.uk/media/1108/sign136\\_2019.pdf](https://www.sign.ac.uk/media/1108/sign136_2019.pdf)
24. Joint Formulary Committee. British National Formulary. London; 2020. Available from: <http://www.medicinescomplete.com>
25. Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. *J Clin Epidemiol* 2009; **62**: 143–8
26. R Core Team. R: A Language and Environment for Statistical Computing. Vienna; 2020. Available from: <https://www.r-project.org/>
27. Davies E, Phillips C, Rance J, Sewell B. Examining patterns in opioid prescribing for non-cancer-related pain in Wales: preliminary data from a retrospective cross-sectional study using large datasets: *Br J Pain* 2018; **13**: 145–58
28. Curtis HJ, Croker R, Walker AJ, Richards GC, Quinlan J, Goldacre B. Opioid prescribing trends and geographical variation in England, 1998-2018: a retrospective database study. *Lancet Psychiatry* 2019; **6**: 140–50

29. Karanges EA, Blanch B, Buckley NA, Pearson SA. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. *Br J Clin Pharmacol* 2016; **82**: 255–67
30. Guy GP, Zhang K, Bohm MK, et al. Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015. *MMWR Morb Mortal Wkly Rep* 2017; **66**: 697–704
31. Jani M, Birlie Yimer B, Sheppard T, Lunt M, Dixon WG. Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study. *PLOS Med* 2020; **17**: e1003270
32. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. *Lancet Neurol* 2015; **14**: 162–73
33. Moulin DE, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. *Pain Res Manag* 2014; **19**: 328–35
34. Smith BH, Higgins C, Baldacchino A, Kidd B, Bannister J. Substance misuse of gabapentin. *Br J Gen Pract* 2012; **62**: 406–7
35. Montastruc F, Loo SY, Renoux C. Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017. *JAMA* 2018; **320**: 2149–51
36. Fallon M, Hoskin PJ, Colvin LA, et al. Randomized Double-Blind Trial of Pregabalin Versus Placebo in Conjunction With Palliative Radiotherapy for Cancer-Induced Bone Pain. *J Clin Oncol* 2016; **34**: 550–6
37. Peckham AM, Evoy KE, Ochs L, Covvey JR. Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern? *Subst Abus* 2018; **12**: 1178221818801311
38. Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. *Drugs* 2021; **81**: 125–56
39. Torrance N, Veluchamy A, Zhou Y, et al. Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland. *Br J Anaesth* 2020; **125**: 159–67
40. Health and Social Care Board. Northern Ireland Medicines Management Newsletter - July 2021 - Volume 12, Issue 7. Belfast; 2021. Available from: [https://hscbusiness.hscni.net/pdf/MM Newsletter July 2021 260721.pdf](https://hscbusiness.hscni.net/pdf/MM%20Newsletter%20July%2021%20260721.pdf)
41. Chen TC, Chen LC, Knaggs RD. A 15-year overview of increasing tramadol utilisation and associated mortality and the impact of tramadol classification in the United Kingdom. *Pharmacoepidemiol Drug Saf* 2018; **27**: 487–94
42. The National Institute for Health and Care Excellence. Medicines optimisation in chronic pain. 2017 [cited 2022 Jan 20]. Available from: <https://www.nice.org.uk/advice/ktt21>
43. Faculty of Pain Medicine of the Royal College of Anaesthetists. Opioids Aware. 2016 [cited 2022 Jan 20]. Available from: <https://www.fpm.ac.uk/opioids-aware>
44. Collins FS, Koroshetz WJ, Volkow ND. Helping to End Addiction Over the

Long-term: The Research Plan for the NIH HEAL Initiative. *JAMA* 2018; **320**: 129–30

45. Morales DR, Morant S V., MacDonald TM, et al. Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands. *Pharmacoepidemiol Drug Saf* 2020; **29**: 296–305
46. Scottish Government Effective Prescribing and Therapeutics Branch. The Scottish Chronic Pain Prescribing Strategy. Edinburgh; 2018. Available from: <https://www.therapeutics.scot.nhs.uk/pain/>
47. The Royal College of Anaesthetists. Raising the Standards: RCoA quality improvement compendium. London; 2020. Available from: [https://rcoa.ac.uk/sites/default/files/documents/2020-%0A08/21075 RCoA Audit Recipe Book\\_Combined\\_Final\\_25.08.2020\\_0.pdf](https://rcoa.ac.uk/sites/default/files/documents/2020-%0A08/21075%20RCoA%20Audit%20Recipe%20Book_Combined_Final_25.08.2020_0.pdf)
48. Medicines and Healthcare Products Regulatory Agency. Opioids: risk of dependence and addiction. London; 2020. Available from: <https://www.gov.uk/drug-safety-update/opioids-risk-of-dependence-and-addiction>
49. Kemp HI, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. *Br J Anaesth* 2020; **125**: 436–40
50. Hutchinson K, Moreland AME, Amanda AC, Weinman J, Horne R. Exploring beliefs and practice of opioid prescribing for persistent non-cancer pain by general practitioners. *Eur J Pain* 2007; **11**: 93–8
51. White R, Hayes C, Boyes AW, Chiu S, Paul CL. General practitioners and management of chronic noncancer pain: a cross-sectional survey of influences on opioid deprescribing. *J Pain Res* 2019; **12**: 467–75
52. Blake H, Leighton P, van der Walt G, Ravenscroft A. Prescribing opioid analgesics for chronic non-malignant pain in general practice – a survey of attitudes and practice. *Br J Pain* 2015; **9**: 225–32
53. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A cohort study. *Ann Intern Med* 2010; **152**: 85–92
54. Gomes T, Khuu W, Martins D, et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. *BMJ* 2018; **362**: k3207

### Box 1. Model for a controlled interrupted time series analysis

$$Y = \beta_0 + \beta_1 * \text{Time} + \beta_2 * \text{Intervention status} + \beta_3 * \text{Intervention status} * \text{Time} + \beta_4 * \text{Cohort status} + \beta_5 * \text{Cohort status} * \text{Time} + \beta_6 * \text{Cohort status} * \text{Intervention status} + \beta_7 * \text{Cohort status} * \text{Intervention status} * \text{Time}$$

Where Y is the outcome (prescribing rate).

$\beta_{0-3}$  are coefficients representing the control cohort (e.g. gabapentinoid series) where  $\beta_0$  is the intercept or value of the outcome at the start of the study period,  $\beta_1$  is the change in outcome per unit time (trend) before the intervention,  $\beta_2$  is the immediate step change in level following the intervention and  $\beta_3$  is the change in trend following the intervention (relative to the trend before the intervention –  $\beta_1$ ).  $\beta_1$  and  $\beta_3$  can therefore be summed to provide the trend following the intervention.  $\beta_{0-3}$  can also be used in isolation as a standalone model for a single interrupted time series analysis.

$\beta_{4-7}$  are coefficients representing the difference between the case series (e.g. opioid series) and the control series.  $\beta_4$  is the difference in intercept level,  $\beta_5$  is the difference in trend before the intervention,  $\beta_6$  is the difference in immediate change in level following the intervention and  $\beta_7$  is the difference in change in trend following the intervention.  $\beta_5$  and  $\beta_7$  can be summed to provide the difference in trend following the intervention.

Time, intervention status and cohort status relate to variables in the dataset representing the time elapsed since the start of the study period, the pre- or post-intervention period and the time series assignment (e.g. opioids or gabapentinoids).

**Table 1.** Single-group interrupted time series analysis of opioid and gabapentinoid prescribing in Scotland

	Opioids			Gabapentinoids		
	Estimate (95% Confidence Interval)	Standard Error	P value	Estimate (95% Confidence Interval)	Standard Error <sup>a</sup>	P value
Intercept, $\beta_0$	224.46 (219.79, 229.12)	2.33	<0.01	3.62 (0.35, 6.90)	1.64	0.03
Pre-Intervention Trend, $\beta_1$	2.19 (1.97, 2.41)	0.11	<0.01	0.88 (0.67, 1.08)	0.10	<0.01
Change in Level, $\beta_2$	-1.09 (-8.21, 6.03)	3.56	0.76	<b>8.00 (2.27, 13.73)</b>	<b>2.86</b>	<b>0.01</b>
<b>Change in Trend, <math>\beta_3</math></b>	<b>-2.82 (-3.24, -2.40)</b>	<b>0.21</b>	<b>&lt;0.01</b>	<b>0.27 (0.07, 0.47)</b>	<b>0.10</b>	<b>0.01</b>
Post-Intervention Trend, $\beta_{1+3}$	-0.64 (-0.98, -0.29)	0.17	<0.01	1.15 (1.04, 1.26)	0.05	<0.01
<b>Relative Change, %<sup>b</sup></b>	<b>-20.67 (-23.67, -17.77)</b>	<b>n/a</b>	<b>n/a</b>	<b>25.89 (15.13, 42.84)</b>	<b>n/a</b>	<b>n/a</b>
Durbin-Watson Statistic	1.64	n/a	n/a	0.80	n/a	n/a

$\beta_{0-3}$  are coefficients from the single-group interrupted time series analysis model; the intercept represents the outcome at the start of the study period; the relative change is calculated compared to the predicted value at the same time point had the pre-intervention trend continued.

<sup>a</sup>Newey-West

<sup>b</sup>Calculated at quarter 2 2020. 95% confidence interval calculated using model bootstrapping.

**Table 2.** Results of the controlled interrupted time series analysis of opioid prescribing rates adjusted for gabapentinoid prescribing in Scotland

	<b>Estimate (95% Confidence Interval)</b>	<b>Standard Error</b>	<b>P value</b>
Difference in Intercept, $\beta_4$	220.83 (215.85, 225.81)	2.51	<0.01
Difference in Pre-Intervention Trend, $\beta_5$	1.31 (1.07, 1.54)	0.12	<0.01
<b>Difference in Change in Level, <math>\beta_6</math></b>	<b>-9.09 (-16.69, -1.49)</b>	<b>3.84</b>	<b>0.02</b>
<b>Difference in Change in Trend, <math>\beta_7</math></b>	<b>-3.09 (-3.54, -2.64)</b>	<b>0.23</b>	<b>&lt;0.01</b>
Difference in Post-Intervention Trend, $\beta_{5+7}$	-1.78 (-2.13, -1.43)	0.17	<0.01
<b>Adjusted Relative Change, %<sup>a</sup></b>	<b>-24.85 (-28.25, -21.61)</b>	<b>n/a</b>	<b>n/a</b>
Durbin-Watson Statistic	1.53	n/a	n/a

$\beta_{4-7}$  are coefficients from the controlled interrupted time series analysis model; the intercept represents the outcome at the start of the study period; the relative change is calculated compared to the predicted value at the same time point had the pre-intervention trend continued.

<sup>a</sup>Calculated at quarter 2 2020. 95% confidence interval calculated using model bootstrapping

**Table 3.** Results of the single interrupted time series analyses of weak and strong opioid prescribing rates in Scotland

	Weak <sup>1</sup>			Strong <sup>2</sup>		
	Estimate (95% Confidence Interval)	Standard Error	P value	Estimate (95% Confidence Interval)	Standard Error	P value
Intercept, $\beta_0$	189.29 (185.48, 193.09)	1.90	<0.01	35.17 (34.15, 36.19)	0.51	<0.01
Pre-Intervention Trend, $\beta_1$	1.36 (1.18, 1.54)	0.09	<0.01	0.82 (0.77, 0.87)	0.02	<0.01
Change in Level, $\beta_2$	-0.34 (-6.15, 5.47)	2.90	0.91	-0.75 (-2.30, 0.80)	0.77	0.34
<b>Change in Trend, <math>\beta_3</math></b>	<b>-2.27 (-2.61, -1.93)</b>	<b>0.17</b>	<b>&lt;0.01</b>	<b>-0.55 (-0.64, -0.46)</b>	<b>0.05</b>	<b>&lt;0.01</b>
<b>Post-Intervention Trend, <math>\beta_{1+3}</math></b>	<b>-0.91 (-1.17, -0.64)</b>	<b>0.13</b>	<b>&lt;0.01</b>	<b>0.27 (0.18, 0.36)</b>	<b>0.04</b>	<b>&lt;0.01</b>
<b>Relative Change, %<sup>a</sup></b>	<b>-21.68 (-24.75, -18.57)</b>	<b>n/a</b>	<b>n/a</b>	<b>-17.49 (-20.15, -14.87)</b>	<b>n/a</b>	<b>n/a</b>
Durbin-Watson Statistic	1.63	n/a	n/a	1.57	n/a	n/a

$\beta_{0-3}$  are coefficients from the single-group interrupted time series analysis model; the intercept represents the outcome at the start of the study period; the relative change is calculated compared to the predicted value at the same time point had the pre-intervention trend continued.

<sup>1</sup>Weak opioids are the following and their compounds: codeine, dihydrocodeine, meptazinol and tramadol

<sup>2</sup>Strong opioids are the following and their compounds: buprenorphine, diamorphine, dipipanone, fentanyl, hydromorphone, methadone, morphine, oxycodone, papaveretum, pentazocine, pethidine and tapentadol

<sup>a</sup>Calculated at quarter 2 2020. 95% confidence interval calculated using model bootstrapping

**Figure 1.** Opioid prescribing time series in Scotland before and after the publication of SIGN 136 in December 2013 (red dashed line). The solid lines represent the prescribing trend derived from the interrupted time series analysis.




**Figure 2.** Prescribing time series of weak<sup>1</sup> and strong<sup>2</sup> opioids in Scotland, before and after the publication of SIGN 136 in December 2013 (red dashed line). The solid lines represent the prescribing trend derived from the interrupted time series analysis.

<sup>1</sup>Weak opioids are the following and their compounds: codeine, dihydrocodeine, meptazinol and tramadol

<sup>2</sup>Strong opioids are the following and their compounds: buprenorphine, diamorphine, dipipanone, fentanyl, hydromorphone, methadone, morphine, oxycodone, papaveretum, pentazocine, pethidine and tapentadol

# Opioid and Gabapentinoid Prescribing in Scotland

SIGN 138



## Opioid Prescribing in Scotland by Strength

